Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late?

BACKGROUND AIMS: Evidence regarding the extent that mesenchymal stromal cells (MSCs) may improve clinical outcomes in patients with coronavirus disease 2019 (COVID-19) has been limited by marked inter-study heterogeneity, inconsistent product characterization and appreciable risk of bias (RoB). Give...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirkham, Aidan M., Bailey, Adrian J.M., Shorr, Risa, Lalu, Manoj M., Fergusson, Dean A., Allan, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Society for Cell & Gene Therapy. Published by Elsevier Inc. 2023
Materias:
Full-Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556962/
https://www.ncbi.nlm.nih.gov/pubmed/36333234
http://dx.doi.org/10.1016/j.jcyt.2022.10.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556962/
https://www.ncbi.nlm.nih.gov/pubmed/36333234
http://dx.doi.org/10.1016/j.jcyt.2022.10.003

Ejemplares similares